Add time:08/12/2019         Source:sciencedirect.com

BackgroundPatients with metabolic bone diseases often have high risk of titanium implant failure due to compromised bone regeneration ability. Clinical evidence indicates that the poor osteogenic ability is partly because of excessive oxidative stress. To date, specific treatments for these patients are urgently needed. Ebselen, a non-toxic organoselenium compound, is reported to be a potent antioxidant agent. In this study, we hypothesized that ebselen exerted protective effects on osteogenic differentiation of bone-marrow-derived mesenchymal stem cells (BMSCs) under oxidative stress.

We also recommend Trading Suppliers and Manufacturers of Ebselen Oxide (cas 104473-83-8). Pls Click Website Link as below: cas 104473-83-8 suppliers